A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
Latest Information Update: 03 Aug 2015
At a glance
- Drugs Blisibimod (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- Acronyms BRILLIANT-SC
- Sponsors Anthera Pharmaceuticals
- 29 Jul 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 10 Feb 2014 New trial record